A Randomized, Double-Blind, Placebo-Controlled Trial of Moclobemide in Patients With Chronic Fatigue Syndrome

Ib, Hickie; Aj, Wilson; Jm, Wright; Bk, Bennett; Wakefield, Denis; Ar, Lloyd

doi:10.4088/jcp.v61n0909

Cited by 66 publications

(31 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…35 One RCT showed an overall beneficial effect of oral NADH (reduced nicotinamide adenine dinucleotide), 36 and 1 controlled trial of selegiline reported some positive effects but found no overall effect. 37 Randomized controlled trials of moclobemide, 38 sulbutiamine, 39 growth hormone, 12 galanthamine hydrobromide, 40 2 RCTs of fludrocortisone 41,42 and 2 of antidepressants 43,44 found no effects of the interventions. A further RCT that assessed the combined effects of GET and fluoxetine found no effect of fluoxetine either on its own or in combination with GET.…”

Section: Pharmacological Resultsmentioning

confidence: 99%

“…15 A negative effect for 1 of the outcomes investigated was found in an RCT of acyclovir. 45 Adverse effects serious enough to cause people to withdraw from the study occurred with fludrocortisone, 42 moclobemide, 38 sulbutiamine, 39 galanthamine hydrobromide, 40 and antidepressants. 43,44 In the galanthamine hydrobromide study, the dosage had to be reduced in 30% of participants due to adverse effects, mainly nausea.…”

Section: Pharmacological Resultsmentioning

confidence: 99%

“…21,27,28,38,48 One study used both the 1988 and the 1994 CDC criteria to diagnose participants, and was classified as using 1994 CDC criteria because these are stricter than the earlier criteria. 42 One study used both the Oxford and 1994 CDC criteria.…”

Section: Diagnostic Criteriamentioning

confidence: 99%

See 2 more Smart Citations

Interventions for the Treatment and Management of Chronic Fatigue Syndrome

Whiting¹,

Bagnall²,

Sowden³

et al. 2001

JAMA

450

273

View full text Add to dashboard Cite

Overall, the interventions demonstrated mixed results in terms of effectiveness. All conclusions about effectiveness should be considered together with the methodological inadequacies of the studies. Interventions which have shown promising results include cognitive behavioral therapy and graded exercise therapy. Further research into these and other treatments is required using standardized outcome measures.

show abstract

Section: Pharmacological Resultsmentioning

confidence: 99%

Section: Pharmacological Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Interventions for the Treatment and Management of Chronic Fatigue Syndrome

Whiting¹,

Bagnall²,

Sowden³

et al. 2001

JAMA

450

273

View full text Add to dashboard Cite

show abstract

“…B. Amitriptylin liegen bescheidene Besserungsraten vor (Goodnick u. Sandoval 1993). Dies gilt auch für den irreversiblen MAO-Hemmer Phenelzin (Natelson et al 1996), den selektiven reversiblen MAO-A-Hemmer Moclobemid (Hickie et al 2000) und den MAO-B-Hemmer Selegilin (Natelson et al 1998) in jeweils doppelblinden, plazebokontrollierten Studien.…”

Section: Empirische Studienunclassified

Psychopharmakotherapie somatoformer Störungen und funktioneller somatischer Syndrome

Kapfhammer

2007

Psychiatrie

View full text Add to dashboard Cite

Patients presenting with bodily symptoms and complaints that are not explained by organic pathology or well known pathophysiological mechanisms form a major challenge to any health delivery system. From a perspective of psychiatric classification these medically unexplained somatic symptoms may be diagnosed as depressive and anxiety disorders on the one hand, as somatoform disorders on the other. Among medical specialties a separate diagnostic approach is taken to conceptualize functional somatic syndromes. From a therapeutic perspective psychotherapeutic strategies play a decisive role. There are also important issues that form a rationale for psychopharmacological interventions. The empirically significant overlap of somatoform syndromes and anxiety and depressive disorders, the conceptualization as affective spectrum disorders, the prominent role of pain symptoms, major neurobiological factors of underlying stress mechanisms, and high rates of psychiatric comorbidity in the often chronic courses of illness also stress the importance of psychopharmacotherapy. A survey will be presented on empirical studies of psychopharmacotherapy in somatoform disorders and some specific somatisation syndromes as fibromyalgia, chronic fatigue syndrome, irritable bowel syndrome, and premenstrual syndrome. Findings of the antidepressant treatment of somatic symptoms in major depression will be summarised.

show abstract

“…In addition, the results of one double-blind trial also reports treatment with moclobemide to be more effective than treatment with SSRIs in atypical depression (Lonnqvist et al, 1994), but two subsequent double-blind trials did not support this finding for phenelzine (Pande et al, 1996), or moclobemide (Sogaard et al, 1999). In parallel, while the MAOIs also seem to be effective in the treatment of chronic fatigue syndrome (Hickie et al, 2000;Natelson et al, 1996Natelson et al, , 1998, studies do not show any effect of the SSRIs on chronic fatigue syndrome (Vercoulen et al, 1996). Although, to date, there are no double-blind studies comparing the relative efficacy of MAOIs versus the SSRIs or TCAs in the treatment of fatigue in depression, the above studies suggest a potential advantage for MAOIs over SSRIs.…”

Section: Side-effect Profilementioning

confidence: 99%

Monoaminergic‐based Pharmacotherapy for Depression

Papakostas¹,

Fava²

2005

Biology of Depression

View full text Add to dashboard Cite

Although recent advances in neuropharmacology, neuroendocrinology, molecular biology, and pharmacogenetics have been instrumental in bringing about potential treatments for depression which are fundamentally unrelated to their predecessors, including substance P antagonists, glutaminergic agents, and corticotropinreleasing factor (CRF) antagonists, nevertheless it was agents that influenced the function of monoamine receptors and transporters that were discovered initially by serendipity and then developed as treatments for depression. The development of such compounds also served as a framework for the understanding of depression as a medical illness affecting brain functioning. As a result of these efforts, our field has gained further understanding of the role of monoamines in depression. In previous chapters, the relevance of monoamines in the underlying pathophysiology of depression was reviewed. In the following chapter we will focus on describing the contemporary role of monoaminergic agents in the treatment of depression. 6.

show abstract

A Randomized, Double-Blind, Placebo-Controlled Trial of Moclobemide in Patients With Chronic Fatigue Syndrome

Cited by 66 publications

References 0 publications

Interventions for the Treatment and Management of Chronic Fatigue Syndrome

Interventions for the Treatment and Management of Chronic Fatigue Syndrome

Psychopharmakotherapie somatoformer Störungen und funktioneller somatischer Syndrome

Monoaminergic‐based Pharmacotherapy for Depression

Contact Info

Product

Resources

About